Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA USA
Culture is key and all Bicycle employees actively embrace and role model our company values:
The Translational Sciences and Diagnostics department is looking to hire a Director to support and oversee the development and execution of Translational strategies for our emerging pipeline of preclinical Bicycle Drug and Radio-conjugate programs. In collaboration with our Research and Innovation (R&I) colleagues, the successful candidate will be responsible for advising on target selection, developing predictive and pharmacodynamic (PD) biomarker strategies, including developing PK-PD-E modelling, and investing in clinical biomarker assay development to support pre-clinical assets from concept to Candidate Selection. Execution of the duties of this role will require co-ordination of activities supporting biomarker strategies internally within and across the Translational Sciences and R&I departments as well as managing scientific studies with a range of CRO’s, external collaborators and clinical investigators. The aim of these studies will be to gain a deep understanding of portfolio asset MOA alongside development of patient stratification and/or PD biomarkers. This position will report to the SVP of Translational Sciences & Diagnostics.
Essential:
Desirable:
Bicycle Therapeutics is committed to building a diverse workforce that is representative of the communities we serve. We recognize that diverse and inclusive teams build a stronger and more innovative company. Therefore, all qualified applicants will be considered for employment, and we do not discriminate on the basis of race, religion, colour, gender, sexual orientation, age, disability status, marital status, or veteran status.